“The positive outlook reflects the significant strengthening of the center’s balance sheet in fiscal 2015, driven by its investment in Juno Therapeutics and subsequent liquidation of a portion of that stock, which significantly bolstered its cash and investment levels,” said S&P analyst Jessica Matsumori.
“The center now has good financial resource ratios for the rating, which we believe may grow to levels more consistent with a higher rating during the next two years,” she added.
More articles on healthcare finance:
Officials nix closure, extend Laurel Regional’s inpatient services
RCM company Health Check expands with new Missouri office
How is Montana’s Medicaid expansion working so far?
